[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience]. - Archive ouverte HAL
Article Dans Une Revue Bulletin du Cancer Année : 2017

[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].

Expérience de l’institut Paoli-Calmettes concernant la chimiothérapie à haute dose et autogreffe de cellules souches hématopoïétiques pour la prise en charge des cancers mammaires : impact du statut Her2 et BRCA1/2

Jean-Marie Boher
Jean-Marc Extra
  • Fonction : Auteur
  • PersonId : 934206

Résumé

Studies evaluating chemotherapy high dose chemotherapy with autologous haematopoietic stem cell transplantation (HDC-ACSH) in the treatment of metastatic (MBC), locally advanced (LABC) and inflammatory (IBC) breast cancer have in common lack of biomarker information, in particular the HER2 status.
Fichier non déposé

Dates et versions

hal-01788977 , version 1 (17-05-2018)

Identifiants

Citer

Laurys Boudin, Christian Chabannon, Patrick Sfumato, Renaud Sabatier, François Bertucci, et al.. [Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].. Bulletin du Cancer, 2017, 104 (4), pp.332 - 343. ⟨10.1016/j.bulcan.2016.12.007⟩. ⟨hal-01788977⟩

Collections

CNRS UNIV-AMU CRCM
48 Consultations
0 Téléchargements

Altmetric

Partager

More